


*Supplementary Material*

# Deciphering Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Reveals the Poor Prognostic Factor of RASSF2 Gene Silencing in Colon Cancers


Marc Riffet, Yassine Eid, Maxime Faisant, Audrey Fohlen, Benjamin Menahem, Arnaud Alves, Fatéméh Dubois, Guénaelle Levallet and Céline Bazille

**Table S1.** List of primers used for MS-PCR for methylated (M) and non-methylated (U) genes.


| <i>RASSF1A</i> | <b>Primer sequences</b>                                                        | <b>Tm(°C)</b> |
|----------------|--------------------------------------------------------------------------------|---------------|
| U              | F: 5'-TTGGTGGAGTGTGTTATGTG-3'<br>R: 5'-CAACCCCCACAAACTAAAAACAA-3'              | 60            |
|                | M: F: 5'-GTGTTAACCGCGTTGCGTATC-3'<br>R: 5'-AACCCCGCGAAGTAAAAACGA-3'            |               |
| <i>RASSF2</i>  |                                                                                |               |
|                | U: F: 5'-AGTTGTTGTTGTTAGGTGG-3'<br>R: 5'-AAAAAACCAACAACCCCCACA-3'              | 63            |
| M              | M: F: 5'-GTTCGTCGTCGTTTAGGCG-3'<br>R: 5'-AAAAACCAACGACCCCCGCG-3'               | 63            |
|                |                                                                                |               |
| <i>STK4</i>    |                                                                                |               |
|                | U: F: 5'-TTTGTGGGTGGGTTAGGAGGTTGT-3'<br>R: 5'-AACCAATAACCCCTCACCAACACAACAA-3'  | 63            |
| M              | M: F: 5'-CGGGGGCGGGTTAGGAGGTC-3'<br>R: 5'-CCAATAACCCCTCACCGACCG-3'             | 63            |
|                |                                                                                |               |
| <i>STK3</i>    |                                                                                |               |
|                | U: F: 5'-TTTAAGTGGGAGGGAGATTGTTGTGG-3'<br>R: 5'-AAAAACAAAACACCAACCAACCAAACC-3' | 61            |
| M              | M: F: 5'-CGGGAGGGAGATTGTCGCG-3'<br>R: 5'-AAACCGAAACACCGACCGACCG-3'             | 63            |
|                |                                                                                |               |
| <i>LATS1</i>   |                                                                                |               |
|                | U: F: 5'-TGAATGATTAGAGTTGTGGGTATGT-3'<br>R: 5'-AACATTCCCAACATCACTTACACA-3'     | 60            |
| M              | M: F: 5'-GAACGATTAGAGTTGCGGGCGAC-3'<br>R: 5'-AACATTCCCGACGTCGCTTACG-3'         | 62            |
|                |                                                                                |               |
| <i>LATS2</i>   |                                                                                |               |
|                | U: F: 5'-GGTGTGTTGGATTGGTATGTGGTT-3'<br>R: 5'-CATCTTCCAAAACACTCACACCACA-3'     | 60            |
| M              | M: F: 5'-TTCGTTGGATTGGTATGCGGTC-3'<br>R: 5'-CCATCTTCCCGAAACGCTCACG-3'          | 60            |
|                |                                                                                |               |




**Figure S1.** Illustrations of the different grades of differentiation of adenocarcinomas. (A) well differentiated adenocarcinoma: well individualized glandular structures, more or less branched (HES  $\times 20$ ). (B and C) Moderately differentiated adenocarcinoma: glandular structures of cribriform appearance, appearance of fused glands (HES  $\times 20$  and  $\times 100$ ). (D) Poorly differentiated adenocarcinoma: formation of clumps, with rare persistent glandular lumens (HES  $\times 100$ ).




**Figure S2.** Illustration of the histological criteria of the cohort. (A) Tumor venous and lymphatic emboli. Tumor cell clusters are located in lymphatics (blue arrow), as well as in venous (black arrows) (HES  $\times 50$ ). (B) Illustration of a tumor deposit located in the mesocolon without identifiable lymph node parenchyma (HES  $\times 20$ ). (C) Illustration of grade 2 budding: a few isolated cells or clusters of less than 5 cells are seen detaching from the tumor glands (HES  $\times 200$ ). (D) Grade 3 budding: many single cells or clusters of less than 5 cells are detached from the tumor glands (HES  $\times 200$ ).



**Figure S3.** Illustration of deficient MMR (dMMR) status. (A) Example of a loss of MLH1 expression in favor of a dMMR-IHC ( $\times 20$ ). (B) The same specimen with expression of MSH2 ( $\times 20$ ).



**Figure S4.**: Heat map of clinical and histological data of the cohort.



**Figure S5:** Low RASSF2 mRNA expression predicts significant worse overall survival in 438 patients with colon cancer from the Table 336. or weakly ( $n = 102$ ) expresses the RASSF2 messenger. Survival analysis reveals that the low RASSF2 mRNA expression predicts significant worse overall survival in 438 patients with colon cancer (P score: 0.038, Expression of RASSF2 in colorectal cancer—The Human Protein Atlas).